These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 32697050)

  • 1. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors.
    Shen YY; Ma XL; Wang M; Zhuang C; Ni B; Tu L; Liu Q; Zhao WY; Cao H
    Cancer Med; 2020 Sep; 9(18):6485-6496. PubMed ID: 32697050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors.
    Guenat D; Deroo O; Magnin S; Chaigneau L; Monnien F; Borg C; Mougin C; Emile JF; Prétet JL
    Oncol Rep; 2017 Mar; 37(3):1671-1681. PubMed ID: 28098915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.
    Capelli L; Petracci E; Quagliuolo V; Saragoni L; Colombo P; Morgagni P; Calistri D; Tomezzoli A; Di Cosmo M; Roviello F; Vindigni C; Coniglio A; Villanacci V; Catarci M; Coppola L; Alfieri S; Ricci R; Capella C; Rausei S; Gulino D; Amadori D; Ulivi P;
    Eur J Surg Oncol; 2016 Aug; 42(8):1206-14. PubMed ID: 27265040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
    Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
    Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
    Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
    Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.
    Hou YY; Grabellus F; Weber F; Zhou Y; Tan YS; Li J; Shen KT; Qin J; Sun YH; Qin XY; Bockhorn M; Gerken G; Broelsch CE; Frilling A
    J Gastrointest Surg; 2009 Sep; 13(9):1583-92. PubMed ID: 19291337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular spectrum of c-KIT and PDGFRA gene mutations in gastro intestinal stromal tumor: determination of frequency, distribution pattern and identification of novel mutations in Indian patients.
    Ahmad F; Lad P; Bhatia S; Das BR
    Med Oncol; 2015 Jan; 32(1):424. PubMed ID: 25481675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
    He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
    Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
    Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
    J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
    Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
    Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study.
    Tsai HJ; Shan YS; Yang CY; Hsiao CF; Tsai CH; Wang CC; Lin MT; Ting CF; Chan DC; Chen TH; Yen CC; Chen YY; Lin HY; Yeh TS; Ho CL; Shieh TY; Bai LY; Hsu JT; Chen IS; Chen LT; Yeh CN;
    BMC Cancer; 2024 Jul; 24(1):828. PubMed ID: 38992597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
    Ali Abuderman AW; M Aldakheel F
    Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.